Last10K.com

Aerpio Pharmaceuticals, Inc. (ARPO) SEC Filing 8-K Material Event for the period ending Monday, January 8, 2018

SEC Filings

Aerpio Pharmaceuticals, Inc.

CIK: 1422142 Ticker: ARPO

View differences made from one to another to evaluate Aerpio Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aerpio Pharmaceuticals, Inc..

Continue

Assess how Aerpio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aerpio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Aerpio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ARPO
CIK: 1422142
Form Type: 8-K Corporate News
Accession Number: 0001193125-18-005248
Submitted to the SEC: Mon Jan 08 2018 9:07:00 AM EST
Accepted by the SEC: Mon Jan 08 2018
Period: Monday, January 8, 2018
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/arpo/0001193125-18-005248.htm